Medical Oncology

Uzm. Dr. Yaşar Culha

Doctor and researcher Sivas Numune Hastanesi Sivas
Carcinoma, Transitional CellNeoplasmsBreast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Transitional Cell 2 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Neoplasms 2 publications
  • Breast Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionSivas Numune Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Transitional CellExtracted from 2 publications · Model version —From source
  • Publications22 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-0317-7552ORCIDFrom source
  • Last synchronised5 November 2026 10:34https://sivasnumunedh.saglik.gov.tr/TR-808521/hekimlerimiz.html#yasar-culhasaglik.gov.tr

Scientific work

Publications on Carcinoma, Transitional Cell

22 publications

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Open-access full textSource: OpenAlex

  2. Palliative Care Awareness Among Caregivers of Cancer Patients in Turkey: A Cross-Sectional Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33080458 PMID 42645362 Open-access full textSource: OpenAlex

  3. Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy—A Real-World Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33070381 PMID 42505183 Open-access full textSource: ORCID

  4. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62030538 PMID 41901620 1 citation (Europe PMC) Open-access full textSource: ORCID

  5. ARE mGPS, SIS, AND LCS SIGNIFICANT IN PREDICTING FIRST-LINE PALLIATIVE CHEMOTHERAPY RESPONSE AND PROGNOSIS IN PATIENTS WITH METASTATIC GASTRIC CANCER?

    Zenodo (CERN European Organization for Nuclear Research), 2026

    DOI 10.5281/zenodo.18936420 Open-access full textSource: OpenAlex

  6. TREATMENT RESULTS IN COLORECTAL CANCER PATIENTS OVER 75 YEARS OF AGE

    Kocatepe Tıp Dergisi, 2026

    DOI 10.18229/kocatepetip.1739344 Open-access full textSource: ORCID

  7. Prognostic Value of the Lung Immune Prognostic Index (LIPI) in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15031188 PMID 41682869 Open-access full textSource: ORCID

  8. THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA

    Kocatepe Tıp Dergisi, 2026

    DOI 10.18229/kocatepetip.1576255 Open-access full textSource: ORCID

  9. Functional Mobility as a Prognostic Marker in Geriatric Oncology: A Prospective Study Using Gait Speed

    Medicina, 2026

    DOI 10.3390/medicina62091815 PMID 42796422 Open-access full textSource: ORCID

  10. The rate of anemia in shift health workers in a university hospital

    Annals of Clinical and Analytical Medicine, 2026

    DOI 10.4328/acam.22935 Open-access full textSource: ORCID

View all 22 publications